ProPhase Labs, Inc. (PRPH) Form 10-K — Jun 1, 2026
ProPhase Labs reported a net loss of $14.7 million for the fiscal year ended December 31, 2025, with revenue declining 35.8% to $4.3 million. The company holds only $90,000 in cash and faces a $49.9 million working capital deficit, prompting explicit going-concern language in the filing. The company’s diagnostic subsidiaries, ProPhase Diagnostics, filed for Chapter 11 bankruptcy in September 2025 due to the collapse of COVID-19 testing demand. ProPhase Labs has deconsolidated these entities from its financial statements and is pursuing reorganization to collect accounts receivable.
Key figures
- Revenue
- 4300000
- Total Debt
- 0
- Cash Position
- 90000
- Shares Outstanding
- 14016025
Price after filing
Close on the filing date to close N calendar days later (from $0.12). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.